KIR3DL1 and non-small cell lung carcinoma: In addition to the association of KIR-ligands present with improved outcome for TNBC patients, shown above in Fig. 2, we note that the KIR2DL2/HLA-C1 associations (Supplementary Table S5B) are conserved in some of the clinical parameters for metastatic urothelial cancer (mUC; OR p = 0.05, tumor shrinkage p = 0.003) and non-small cell lung cancer (NSCLC; tumor shrinkage p = 0.05).